By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Boehringer Ingelheim And Eli Lilly (LLY) To Support New American College Of Cardiology Program To Highlight The Increasingly Important Role Of Cardiologists In Reducing Cardiovascular Risk And Cardiovascular Death In People With Type 2 Diabetes 7/31/2017 2:53:50 PM
Boehringer Ingelheim Starts Clinical Study On Interchangeability Between Its Adalimumab Biosimilar Candidate And U.S.-Formulated Humira 7/27/2017 10:58:25 AM
Boehringer Ingelheim Starts Clinical Study On Interchangeability Between Its Adalimumab Biosimilar Candidate And HUMIRA 7/27/2017 8:49:36 AM
Boehringer Ingelheim Release: People With Idiopathic Pulmonary Fibrosis (IPF) Reveal High Burden Of Disease In New Survey 7/24/2017 8:17:57 AM
Boehringer Ingelheim Aims for 300 New Bay Area Jobs With $217 Million Expansion 7/24/2017 5:53:39 AM
Philogen S.p.A. Enters Into Multi-Target Research Agreement With Boehringer Ingelheim In The Field Of DNA-Encoded Chemistry 7/20/2017 7:34:54 AM
The Quest of the Ambitious New Generation of Family-Run Boehringer Ingelheim 7/17/2017 6:56:41 AM
Boehringer Ingelheim Release: Final Phase III Study Results Confirm Benefit Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017 6:49:25 AM
Boehringer Ingelheim Release: Final Phase III Study Results Reinforces Safety And Efficacy Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017 6:38:43 AM
Bay Area's Kindred Bio (KIN) Scoops Up Boehringer Ingelheim's Former Space in Kansas 6/26/2017 5:51:17 AM
12345678910...
//-->